Core Viewpoint - Qingdao Guoen Technology Co., Ltd. (referred to as "Guoen Technology") has successfully listed on the Hong Kong Stock Exchange, closing at HKD 40.16 with an increase of 11.56% on the first day of trading [1]. Group 1: Company Overview - Guoen Technology specializes in the supply of new chemical materials and upstream and downstream products of gelatin and collagen [1]. - The company issued a total of 30,000,000 shares, with 3,000,000 shares available for public offering in Hong Kong and 27,000,000 shares for international offering [2]. Group 2: Financial Details - The final offering price was set at HKD 36.00, resulting in total proceeds of HKD 1,080.0 million. After deducting estimated listing expenses of HKD 79.6 million, the net proceeds amounted to HKD 1,000.4 million [2][3]. - The net proceeds from the global offering will be used for establishing a new production base in Thailand to expand capacity, enhancing the production capacity of the new base in Yixing, China, and general corporate purposes [3]. Group 3: Investor Information - Key cornerstone investors include Liguan Investment Co., Ltd., SLD International Enterprises Limited, and several others, with varying percentages of share allocation [5][6].

Core Viewpoint - The report highlights the premium rates of AH shares, with Northeast Electric, Zhejiang Shibao, and Sinopec Oilfield Services leading in premium rates, while CATL, China Merchants Bank, and WuXi AppTec are at the bottom of the list [1][2]. Premium Rate Rankings - The top three AH shares by premium rate are: - Northeast Electric (00042) with a premium rate of 815.25% - Zhejiang Shibao (01057) with a premium rate of 351.07% - Sinopec Oilfield Services (01033) with a premium rate of 303.37% [2] - The bottom three AH shares by premium rate are: - CATL (03750) with a premium rate of -12.99% - China Merchants Bank (03968) with a premium rate of -1.83% - WuXi AppTec (02359) with a premium rate of 3.29% [2] Deviation Values - The top three shares by deviation value are: - Guoen Technology (02768) with a deviation value of 64.57% - Goldwind Technology (02208) with a deviation value of 30.74% - Sinopec Oilfield Services (01033) with a deviation value of 27.72% [1][2] - The bottom three shares by deviation value are: - Junda Co., Ltd. (02865) with a deviation value of -49.44% - Zhejiang Shibao (01057) with a deviation value of -46.76% - Yangtze Optical Fibre and Cable (06869) with a deviation value of -34.58% [1][3].

Market Overview - The US stock market experienced a decline, with the Chinese concept index dropping by 0.94%. The Hang Seng Index fell by 110.27 points, a decrease of 0.41%, closing at 26,724.50 points, while the Hang Seng Tech Index dropped by 120.19 points, down 2.20%, reaching a new low since mid-July 2025 [1] - Technology stocks, particularly those considered riskier, continued to decline, with Tencent falling nearly 4% after restrictions on its "Yuanbao Red Packet" link by WeChat. Other major players like Baidu, Meituan, and Xiaomi also saw declines of over 2%, while Bilibili dropped nearly 5% [1] - Chip stocks faced significant losses, with Shanghai Fudan down nearly 9%, Huahong Semiconductor down over 5%, and SMIC down nearly 3% [1] - The coal sector showed strength, with Feishang No Smoke Coal rising over 33%. Real estate stocks also performed well, with Sunac China up over 7% and China Resources Land up nearly 4% [1] Corporate Developments - In the technology sector, InnoCare successfully completed a significant design integration for AI hardware with Google, establishing a solid foundation in the AI hardware market [1] - Enoch Intelligent received a milestone payment of HKD 39 million from Menarini, marking a significant step in its pharmaceutical technology research [1] - Capital investment firm Shumeng Capital signed a contract worth USD 3 million with a Macau distributor, expanding its business footprint [1] Pharmaceutical Industry Highlights - Youzhiyou Biotech's M701 received FDA IND approval for a novel therapy targeting malignant pleural effusion, marking a new phase in international clinical development [2] - Xiansheng Pharmaceutical received a milestone payment of USD 40 million from AbbVie for the overseas licensing option agreement for SIM0500, highlighting its competitiveness in the international pharmaceutical market [2] - Kangfang Biotech granted exclusive commercialization rights for Yixinning® to Jichuan Pharmaceutical, resulting in significant licensing fees and milestone payments [2] - Federal Pharmaceuticals' UBT251 injection received implied clinical trial approval for a new indication, providing new treatment options for patients [2] Food Industry Performance - Nissin Foods reported strong performance in its China business segment, with revenue reaching JPY 54.948 billion, a year-on-year increase of 2.7%, and core operating profit of JPY 5.859 billion, up 9.3% [2] Capital Market Insights - Guotai Junan International noted a market shift from "liquidity-driven" to "profit-driven" dynamics, suggesting a focus on fundamental analysis rather than speculative trading [4] - CITIC Securities observed significant adjustments in Hong Kong stock earnings expectations, predicting a continuation of the spring market rally with large-cap stocks outperforming [4] - Huatai Securities indicated that the current market sentiment has shifted to optimism, suggesting a focus on companies with earnings certainty and potential for growth in technology and cyclical sectors [5] - Guoyuan International highlighted that Hong Kong stocks may continue to outperform US stocks due to favorable conditions for non-US assets and the potential recovery of domestic demand [5]

Group 1 - All newly listed stocks in the Hong Kong market this year have seen an increase on their first trading day, with no stocks experiencing a decline [2] - Guoen Technology (02768.HK) officially listed on the Hong Kong Stock Exchange on February 4, with a significant opening increase of 27%, reaching a price of HKD 45.72 [2] - The public offering of Guoen Technology was oversubscribed by 2,251.85 times, with 3 million shares available for public subscription, accounting for 10% of the total offering [3] Group 2 - The international placement of Guoen Technology was oversubscribed by 10.03 times, with 27 million shares allocated, representing 90% of the total offering [3] - The final offer price for Guoen Technology was set at HKD 36.00 per share, which is in the lower-middle range of the pricing range (HKD 34.00 to HKD 42.00), raising approximately HKD 1 billion in net proceeds [3] - Guoen Technology specializes in chemical new materials and collagen products, serving the chemical and health industries, focusing on R&D, production, and sales [4] Group 3 - Guoen Technology operates within the large chemical industry, covering the entire value chain of chemical new materials, including upstream green petrochemical materials and downstream applications in electronics, automotive, and renewable energy sectors [4] - The company has a complete layout from collagen and derivative raw materials to end products, gradually becoming a comprehensive group in the health sector [4] - For the fiscal years 2022 to 2025, Guoen Technology's revenues are projected to be RMB 13.406 billion, RMB 17.439 billion, RMB 19.188 billion, and RMB 17.444 billion, with corresponding profits of RMB 0.724 billion, RMB 0.540 billion, RMB 0.721 billion, and RMB 0.721 billion [4]

从公司基本面来看，国恩科技是一家专注于化工新材料及明胶、胶原蛋白上下游产品的中国供应商，业 务横跨化工行业与大健康行业，主要从事工业及商业用途产品的研发、生产与销售。根据弗若斯特沙利 文的资料，在2024年，按销售收入计算，国恩科技是中国第二大的有机高分子改性材料及有机高分子复 合材料企业，市场份额达到2.5%；同时，按产能计算，它还是中国最大的聚苯乙烯企业，在行业内占 据着重要地位。 2月4日，国恩科技正式在资本市场首挂上市，开启发展新征程。公告显示，国恩科技每股定价36港元， 此次共发行3000万股份，每手交易单位为200股，通过此次发行所得款项净额约10亿港元。上市首日， 国恩科技便展现出强劲的市场表现。截至发稿，其股价大幅上涨25%，报45港元，成交额达2.48亿港 元。 2月4日深交所发布公告，由于国恩科技在香港联合交易所有限公司上市不适用价格稳定期机制，且相应 A股上市已满10个交易日，依据《深圳证券交易所深港通业务实施办法》的相关规定，港股通标的证券 名单作出调整，国恩科技被调入，并将自2026年2月4日起正式生效。 ...

银河证券指出，展望未来，全球地缘政治风险扰动仍存，美联储降息预期下降，预计港股持续震荡。配 置方面，建议关注以下板块：(1)科技板块仍是中长期投资主线，在产业链涨价、国产化替代、AI应用 加速推进等多重利好共振下，有望震荡上行。(2)地缘政治局势反复无常，能源、贵金属(核心股)(核心 股)等板块有望震荡上行。(3)消费板块当前估值处于相对低位，临近春节，促消费政策有望增多，消费 板块有望实现反弹。 华泰证券表示，1月下旬反弹以来，情绪指数在短短16天内就从恐慌区间进入乐观区间，我们在之前也 提示以投资心态而非投机心态看待港股机会。经历了如此调整后，当前的核心问题是波动的持续性和会 不会终结市场表现。当前情绪已在乐观区间，且拥挤度尚未明显回落，波动短期或持续，但更多是回撤 而不是反转。一季度市场空间的三个驱动因素——流动性改善、资金面共振与盈利预期上修仍然成立。 建议更应立足中期视角，重视空间，淡化斜率。板块上以业绩确定性公司作为底仓，近期回调程度较高 的科技+周期耗材主线并未变化，可择机增配。 本文转载自"腾讯自选股"，智通财经编辑：徐文强。 恒生指数低开0.14%，恒生科技指数跌0.87%。科网股走低。国恩 ...

Group 1 - The core viewpoint of the article is that Guoen Technology (02768) has successfully listed on the Hong Kong Stock Exchange, with an initial share price of HKD 36 and a total issuance of 30 million shares, raising approximately HKD 1 billion in net proceeds [1] - As of the report, the stock price has increased by 25%, trading at HKD 45, with a transaction volume of HKD 248 million [1] - Guoen Technology specializes in new chemical materials and upstream and downstream products of gelatin and collagen, serving both the chemical and health industries [1] Group 2 - According to Frost & Sullivan, Guoen Technology is the second-largest company in China for organic polymer modified materials and organic polymer composite materials by sales revenue, holding a market share of 2.5% in 2024 [1] - The company is projected to be the largest producer of polystyrene in China by production capacity in 2024 [1] - On February 4, the Shenzhen Stock Exchange announced that Guoen Technology would be included in the Hong Kong Stock Connect securities list, effective from February 4, 2026, due to its listing on the Hong Kong Stock Exchange not being subject to the price stabilization mechanism [1]

Group 1 - The core viewpoint of the article is that Guoen Technology (02768) has successfully listed on the Hong Kong Stock Exchange, with an initial share price of HKD 36 and a total issuance of 30 million shares, raising approximately HKD 1 billion in net proceeds [1] - As of the report, the stock price has increased by 25%, trading at HKD 45, with a transaction volume of HKD 248 million [1] - Guoen Technology specializes in chemical new materials and upstream and downstream products of gelatin and collagen, serving both the chemical and health industries through research, production, and sales of industrial and commercial products [1] Group 2 - According to Frost & Sullivan, Guoen Technology is the second-largest company in China in terms of organic polymer modified materials and organic polymer composite materials by sales revenue, holding a market share of 2.5% in 2024 [1] - Additionally, Guoen Technology is projected to be the largest producer of polystyrene in China by production capacity in 2024 [1] - On February 4, the Shenzhen Stock Exchange announced that Guoen Technology would be included in the Hong Kong Stock Connect securities list, effective from February 4, 2026, due to the inapplicability of the price stabilization mechanism for its listing on the Hong Kong Stock Exchange [1]

每经AI快讯，2月4日，新股国恩科技在港交所上市，开盘大涨25%，报45港元/股。 ...

港股国恩科技上市首日高开25%，报45港元。公司全球发售3000万股H股，香港公开发售占10%，国际 发售占90%。最终发售价每股36港元，全球发售净筹约10.004亿港元。 来源：滚动播报 ...